A Novel Compound Sclerosant: Polidocanol-Bleomycin Foam

• Published in: Dermatologic surgery Vol. 46; no. 12; p. 1712
• Main Authors: Hanshu, Zhang, Shaohua, Liu, Anwei, Chen
• Format: Journal Article
• Language: English
• Published: United States 01.12.2020
• Subjects: Bleomycin - administration & dosage; Bleomycin - chemistry; Drug Combinations; Drug Compounding - methods; Drug Stability; Half-Life; Humans; Polidocanol - administration & dosage; Polidocanol - chemistry; Sclerosing Solutions - administration & dosage; Sclerosing Solutions - chemistry; Sclerotherapy - methods; Vascular Malformations - therapy; Veins - abnormalities; Veins - drug effects
• ISSN: 1524-4725
• DOI: 10.1097/DSS.0000000000002533

Foam sclerotherapy is an effective treatment strategy for venous malformations. Both polidocanol (POL) and bleomycin are effective sclerosants; however, no studies have reported POL-bleomycin foam. To introduce a method for producing POL-bleomycin foam and evaluate the stability of POL-bleomycin foam with bleomycin concentrations. Group A: 2 mL of 1% POL + 8 mL of air; Group B: 2 mL of 1% POL + 3 U bleomycin + 8 mL of air; Group C: 2 mL of 1% POL + 6 U bleomycin + 8 mL of air; Group D: 2 mL of 1% POL + 12 U bleomycin + 8 mL of air. Tessari method was used for foam generation. The foam half-life time (FHT) was used to evaluate foam stability. Five recordings were made for each group. The FHT was 148.6 ± 2.9 seconds in Group A, 148.8 ± 4.0 seconds in Group B, 148.4 ± 2.6 seconds in Group C, and 148.8 ± 1.6 seconds in Group D. The FHT in different groups showed no significant differences. The POL-bleomycin foam was prepared successfully and its FHT was as long as the POL foam.